Genome-wide analysis of Ollier disease: Is it all in the genes?
Twinkal C Pansuriya, Jan Oosting, Tibor Krenács, Antonie H M Taminiau, Suzan H M Verdegaal, Luca Sangiorgi, Raf Sciot, Pancras C W Hogendoorn, Karoly Szuhai, Judith V M G Bovée, Twinkal C Pansuriya, Jan Oosting, Tibor Krenács, Antonie H M Taminiau, Suzan H M Verdegaal, Luca Sangiorgi, Raf Sciot, Pancras C W Hogendoorn, Karoly Szuhai, Judith V M G Bovée
Abstract
Background: Ollier disease is a rare, non-hereditary disorder which is characterized by the presence of multiple enchondromas (ECs), benign cartilaginous neoplasms arising within the medulla of the bone, with an asymmetric distribution. The risk of malignant transformation towards central chondrosarcoma (CS) is increased up to 35%. The aetiology of Ollier disease is unknown.
Methods: We undertook genome-wide copy number and loss of heterozygosity (LOH) analysis using Affymetrix SNP 6.0 array on 37 tumours of 28 Ollier patients in combination with expression array using Illumina BeadArray v3.0 for 7 ECs of 6 patients.
Results: Non-recurrent EC specific copy number alterations were found at FAM86D, PRKG1 and ANKS1B. LOH with copy number loss of chromosome 6 was found in two ECs from two unrelated Ollier patients. One of these patients also had LOH at chromosome 3. However, no common genomic alterations were found for all ECs. Using an integration approach of SNP and expression array we identified loss as well as down regulation of POU5F1 and gain as well as up regulation of NIPBL. None of these candidate regions were affected in more than two Ollier patients suggesting these changes to be random secondary events in EC development. An increased number of genetic alterations and LOH were found in Ollier CS which mainly involves chromosomes 9p, 6q, 5q and 3p.
Conclusions: We present the first genome-wide analysis of the largest international series of Ollier ECs and CS reported so far and demonstrate that copy number alterations and LOH are rare and non-recurrent in Ollier ECs while secondary CS are genetically unstable. One could predict that instead small deletions, point mutations or epigenetic mechanisms play a role in the origin of ECs of Ollier disease.
Figures
References
- Lucas DR, Bridge JA. In: World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Fletcher CDM, Unni KK, Mertens F, editor. Lyon: IARC Press; 2002. Chondromas: enchondroma, periosteal chondroma, and enchondromatosis; pp. 237–240.
- Pansuriya T, Kroon HM, Bovée JVMG. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol. 2010;3:557–569.
- Mertens F, Unni KK. In: World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Fletcher CDM, Unni KK, Mertens F, editor. Lyon: IARC Press; 2002. Enchondromatosis: Ollier disease and Maffucci syndrome; pp. 356–357.
- Bovée JVMG, Hogendoorn PCW, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer. 2010;10:481–488.
- Khurana J, Abdul-Karim F, Bovée JVMG. In: World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Fletcher CDM, Unni KK, Mertens F, editor. Lyon (France): IARC Press; 2002. Osteochondroma; pp. 234–236.
- Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, Bell RS, Juppner H, Andrulis IL, Wunder JS. et al.A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet. 2002;30:306–310. doi: 10.1038/ng844.
- Couvineau A, Wouters V, Bertrand G, Rouyer C, Gerard B, Boon LM, Grandchamp B, Vikkula M, Silve C. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet. 2008;17:2766–2775. doi: 10.1093/hmg/ddn176.
- Rozeman LB, Sangiorgi L, Bruijn IH, Mainil-Varlet P, Bertoni F, Cleton-Jansen AM, Hogendoorn PCW, Bovée JVMG. Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hum Mutat. 2004;24:466–473. doi: 10.1002/humu.20095.
- Silve C, Juppner H. Ollier disease. Orphanet J Rare Dis. 2006;1:37. doi: 10.1186/1750-1172-1-37.
- Cohen MM, Jr, Siegal GP. In: World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F, editor. Lyon: IARC Press; 2002. McCune-Albright syndrome; pp. 357–359.
- Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, Stanton SE, Larsson C, Hudson TJ, Johnson BE. et al.Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000;18:1001–1005. doi: 10.1038/79269.
- Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C. et integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004;64:3060–3071. doi: 10.1158/0008-5472.CAN-03-3308.
- Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818–831. doi: 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>;2-B.
- Bovée JVMG, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AHM, Bakker E, Van HW, Cornelisse CJ, Hogendoorn PCW. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet. 1999;65:689–698.
- Miller SA, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. doi: 10.1093/nar/16.3.1215.
- Baelde HJ, Cleton-Jansen AM, van Beerendonk H, Namba M, Bovée JVMG, Hogendoorn PCW. High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma. J Clin Pathol. 2001;54:778–782.
- Lin S, Carvalho B, Cutler DJ, Arking DE, Chakravarti A, Irizarry RA. Validation and extension of an empirical Bayes method for SNP calling on Affymetrix microarrays. Genome Biol. 2008;9:R63. doi: 10.1186/gb-2008-9-4-r63.
- Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics. 2009;25:2149–2156. doi: 10.1093/bioinformatics/btp371.
- Corver WE, Middeldorp A, Ter Haar NT, Jordanova ES, van PM, van ER, Cornelisse CJ, Fleuren GJ, Morreau H, Oosting J. et al.Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations. Cancer Res. 2008;68:10333–10340. doi: 10.1158/0008-5472.CAN-08-2665.
- Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, Orntoft TF. Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis. 2007;28:38–48. doi: 10.1093/carcin/bgl086.
- Knijnenburg J, Oberstein SA, Frei K, Lucas T, Gijsbers AC, Ruivenkamp CA, Tanke HJ, Szuhai K. A homozygous deletion of a normal variation locus in a patient with hearing loss from non-consanguineous parents. J Med Genet. 2009;46:412–417. doi: 10.1136/jmg.2008.063685.
- Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res. 2008;36:e11. doi: 10.1093/nar/gkm1075.
- Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics. 2007;23:2183–2184. doi: 10.1093/bioinformatics/btm311.
- Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3 Article3.
- Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, Van der Woude FJ, Waldherr R, Rabelink TJ, De HE. et al.Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007;71:637–645. doi: 10.1038/sj.ki.5002101.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034.1–0034.11. doi: 10.1186/gb-2002-3-7-research0034.
- Bovée JVMG, Van den Broek LJCM, Cleton-Jansen AM, Hogendoorn PCW. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest. 2000;80:1925–1933.
- McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PI, Maller JB, Kirby A. et al.Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40:1166–1174. doi: 10.1038/ng.238.
- McCarroll SA, Altshuler DM. Copy-number variation and association studies of human disease. Nat Genet. 2007;39:S37–S42. doi: 10.1038/ng2080.
- Rozeman LB, Szuhai K, Schrage YM, Rosenberg C, Tanke HJ, Taminiau AHM, Cleton-Jansen AM, Bovée JVMG, Hogendoorn PCW. Array-comparative genomic hybridization of central chondrosarcoma - Identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. Cancer. 2006;107:380–388. doi: 10.1002/cncr.22001.
- Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C. et al.Signatures of mutation and selection in the cancer genome. Nature. 2010;463:893–898. doi: 10.1038/nature08768.
- Roitt Ivan M. Essential Immunology. Blackwell Scientific Publications; 1988.
- Zakharkin SO, Belay AT, Fernandez JR, De LV, Kennedy JL, Sokolowski MB, Allison DB. Lack of association between polymorphism of the human cyclic GMP-dependent protein kinase gene and obesity. Int J Obes (Lond) 2005;29:872–874. doi: 10.1038/sj.ijo.0802973.
- Fu X, McGrath S, Pasillas M, Nakazawa S, Kamps MP. EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1. Oncogene. 1999;18:4920–4929. doi: 10.1038/sj.onc.1202874.
- Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2:3081–3089. doi: 10.1038/nprot.2007.418.
- Sobreira NL, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, Ge D, Shianna KV, Smith JP, Maia JM. et al.Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet. 2010;6:e1000991. doi: 10.1371/journal.pgen.1000991.
- Ozisik YY, Meloni AM, Spanier SS, Bush CH, Kingsley KL, Sandberg AA. Deletion 1p in a low-grade chondrosarcoma in a patient with Ollier disease. Cancer Genet Cytogenet. 1998;105:128–133. doi: 10.1016/S0165-4608(98)00027-2.
- Bovée JVMG, van Roggen JF, Cleton-Jansen AM, Taminiau AH, Van der Woude HJ, Hogendoorn PCW. Malignant progression in multiple enchondromatosis (Ollier's disease): an autopsy-based molecular genetic study. Hum Pathol. 2000;31:1299–1303.
- Bovée JVMG, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncology. 2005;6:599–607.
- Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH. et al.BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–114. doi: 10.1038/nature06866.
Source: PubMed